Highbridge Capital Management’s Cidara Therapeutics CDTX Stock Holding History

Highbridge Capital Management’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-112,980	Closed	-$25M	–	379
2025 Q4	$25M	Buy	+112,980	New	+$18.3M	0.8%	35

Highbridge Capital Management's CDTX Position: Q1 2026 in Review

Highbridge Capital Management sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 112,980 shares — an estimated $25M sold.

Highbridge Capital Management first reported a position in CDTX in Q4 2025 and held it in 1 quarter. The position peaked at $25M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Highbridge Capital Management reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Highbridge Capital Management sold 112,980 Cidara Therapeutics shares in Q1 2026, an estimated $25M.
Highbridge Capital Management first reported a position in Cidara Therapeutics in Q4 2025 and held it in 1 quarter.
Highbridge Capital Management's Cidara Therapeutics position peaked at $25M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Highbridge Capital Management's 13F filing for Q1 2026, filed 15 May 2026.